..., instructions or products referred to in the content or advertisements. 2023 Hepatitis E Lung cancer Chemotherapy Immune-related adverse event Drug-induced liver injury Acute hepatitis E, one of the causes of acute liver injury, is an infection caused by the hepatitis E virus (HEV) after...

... lung cancer patients. Methods. Patients were treated with concurrent chemoradiotherapy (CRT) using involved-field radiotherapy (RT). Every patient received FARINGEL at the beginning of CRT until the first follow-up. The data of the study group were compared with the data of a control group treated...

... acid improves overall survival (OS) of lung cancer patients with bone metastases receiving chemotherapy. However, it is currently unknown whether zoledronic acid-induced fever is associated with OS. The purpose of this study was to examine the association between zoledronic acid-induced fever...

...Hasan Mutlu; Deniz Arslan; Şeyda Gündüz; Deniz Tural; Abdullah Büyükçelik; Yasemin Benderli Cihan; Tuncay Aslan; Hakan Bozcuk; Hasan Şenol Coşkun Background: Stage IIIB non-small cell lung cancer (NSCLC) consists of T4N2M0 and TXN3M0 NSCLC. In the present study, we aimed to evaluate the efficacy...

... 2009;35:557-560. 5. Ortega J, Hayes JM, Antonia S: Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol 2009;65:187-190. 6. Clemente G, Chiarla C, Giovannini I, De Rose AM...

...Guanhai Dai; Yeling Tong; Xuan Chen; Zeming Ren; Feng Yang Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Despite the new chemotherapy regimens and cytotoxic combinations investigated in multiple clinical trials in recent years, no significant improvement...

... in amrubicin (AMR) therapy. However, the predictive factors for the development of severe neutropenia in AMR therapy remain unknown. Methods: The subjects were 61 advanced lung cancer patients treated with AMR monotherapy. All data were retrospectively collected from the electronic medical record system...

...Kiyoshi Mori; Yukari Kamiyama; Hisashi Kasai; Tetsuro Kodama Background: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). Methods: 46 chemotherapy-naive patients with measurable...

...Fumio Imamura; Makoto Nishio; Rintaro Noro; Masahiro Tsuboi; Norihiko Ikeda; Akira Inoue; Yoshinobu Ohsaki; Yukio Kimura; Kazumi Nishino; Junji Uchida; Takeshi Horai Background: Gemcitabine combined with carboplatin (CG) is one of the regimens used widely for advanced non-small cell lung cancer...

...N.N. Guerrero-Vargas; R. Jurado; J. Virto-Aguilar; P. García-López Background: The activity of steroid hormones for the efficacy of antineoplastic drugs used in lung cancer treatment has not been explored. We evaluated the influence of 17β-estradiol on the cytotoxicity of etoposide in a lung cancer...

...Shinji Teramoto; Yoshinosuke Fukuchi; Chong-Yu Shu; Hajime Orimo Oxygen radical generation by blood cells before and after chemotherapy was investigated in 16 elderly (72.8 ± 1.0 years) and 14 adult (45.0 ± 2.4 years) patients with lung cancer, using a lucigenin-dependent chemiluminescence method...

...Yasuo Saijo; Yushi Nakai; Junichi Saito; Shunichi Sugawara; Shuji Suzuki; Yuka Numata; Masakichi Motomiya Serial serum erythropoietin (EPO) levels were measured in 12 adult lung cancer patients during cancer chemotherapy. In major cases, EPO levels increased significantly after chemotherapy while...

..., instructions or products referred to in the content or advertisements. Lung cancer Cyclophosphamide Vindesine Oral VP-16 Clinical Reports Chemotherapy 34: 155-157(1988) Cyclophosphamide, Vindesine and Oral VP-16 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): An Outpatient Regimen1 Alan B...

... Cefuroxime Cephalosporins Ampicillin Double-blind comparison Chronic bronchitis Pneumonia Bronchiectasis Lung cancer © 1981 S. Karger AG, Basel 1981 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages...

...Shinjiro Nagai; Kazumasa Takenaka; Makoto Sonobe; Hiromi Wada; Fumihiro Tanaka Background: Pemetrexed, a multi-targeted antifolate (MTA), is a promising agent in the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). With the aim of finding an optimal schedule...

... mg/m 2 /dose level, until either a MTD or the final dose of 400 mg/m 2 was reached. Results: Fifteen patients were enrolled in the study. Median age was 58 years. The majority had non-small-cell lung cancer. The study went to completion without reaching an MTD. Hematological toxicities were mild...

..., and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2–54.6%). Conclusion: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing. Phase I trial Cisplatin Irinotecan Dose-limiting toxicity Lung cancer...

...Kenneth J. O’Byrne; Andrew V. Schally; Ann Thomas; Desmond N. Carney; William P. Steward Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease...